rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration.
The binding of selectin to P&mdash;selectin glycoprotein ligand&mdash;1 (PSGL&mdash;1) mediates the tethering and rolling of leukocytes on the endothelium during leukocyte migration and inflammation. Recombinant human PSGL&mdash;1&mdash;Ig fusion protein (rPSGL&mdash;1&mdash;Ig) is a widely used selectin inhibitor that prevents neutrophil entry into inflamed or reperfused tissues. We hypothesized that rPSGL&mdash;1&mdash;Ig could be used to as a drug for the treatment of acute lung injury (ALI). We induced murine ALI by injecting mice with lipopolysaccharide (LPS) and then treated the mice with rPSGL&mdash;1&mdash;Ig. We determined the lung injury index, wet/dry ratio, and inflammatory cytokine level in differentially treated mice. The symptoms of LPS&mdash;induced lung injury were alleviated by rPSGL&mdash;1&mdash;Ig treatment. The histopathological index of LPS&mdash;induced lung injury improved after rPSGL&mdash;1&mdash;Ig treatment. rPSGL&mdash;1&mdash;Ig treatment also reduced the recruitment of inflammatory cells, including neutrophils, into the lung, as well as reducing the level of inflammatory cytokines. These data suggest that rPSGL&mdash;1&mdash;Ig protein has a therapeutic effect on LPS&mdash;induced lung injury.